Solid Biosciences appoints Kevin Tan CFO, discloses $214M cash, targets SGT-003 IND in H2 2023

Solid Biosciences Inc.

Kevin Tan appointed CFO effective Jan 9, 2023; base salary $425k, 40% bonus target, equity grants.
Preliminary cash and investments $214M as of Dec 31, 2022 (unaudited).
Company anticipates submitting IND for SGT-003 in H2 2023 with patient dosing in late 2023.
Tan previously served as CFO of Selecta Biosciences and Treasurer at Sarepta Therapeutics.

item 2.02 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kevin Tan

Chief Financial Officer

SLDB · Solid Biosciences Inc.

Effective: 2023-01-09
Filed: January 9, 2023, 6:59 PM ET

On January 6, 2023, the Company’s Board of Directors (the “Board”) appointed Kevin Tan as the Company’s Chief Financial Officer, effective as of January 9, 2023

Departed (interim)

Stephen DiPalma

Interim Chief Financial Officer

SLDB · Solid Biosciences Inc.

Effective: 2023-01-09
Successor: Kevin Tan
Filed: January 9, 2023, 6:59 PM ET

In connection with Mr. Tan’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer and principal financial officer and principal accounting officer, will cease to serve in such roles, effective as of the Appointment Date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin Tan was appointed as Chief Financial Officer at Solid Biosciences Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On January 6, 2023, the Company’s Board of Directors (the “Board”) appointed Kevin Tan as the Company’s Chief Financial Officer, effective as of January 9, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen DiPalma departed as Interim Chief Financial Officer at Solid Biosciences Inc..

Action: ceased to serve
Role: Interim Chief Financial Officer

Exact text from the filing

In connection with Mr. Tan’s appointment, Stephen DiPalma, the Company’s Interim Chief Financial Officer and principal financial officer and principal accounting officer, will cease to serve in such roles, effective as of the Appointment Date.

View on SEC.gov

Solid Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-004189

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.